Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Comparing Liposomal Bupivacaine Versus Standard Bupivacaine in Colorectal Surgery

NCT03702621 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to compare the difference between two different pain control methods in patients who will be having a colorectal surgery

Conditions Studied

Interventions

  • DRUG Bupivacaine Hydrochloride
  • DRUG liposomal Bupivacaine

Study Locations (1)

Indiana

  • Indiana University Hospital — Indianapolis

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2018-08-30
Est. Completion 2020-03-13
Phase Phase 3

Sponsor

Indiana University

1,026 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03702621

The ClinicalTrials.gov registry entry for NCT03702621 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 1,026 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Colorectal Surgery appearing as the primary indexed condition, and to 2 interventions — of which Bupivacaine Hydrochloride is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03702621 reports 1 study location spanning 1 distinct geographic area — top geographies include Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03702621 about?

NCT03702621 is a clinical study titled "Comparing Liposomal Bupivacaine Versus Standard Bupivacaine in Colorectal Surgery". The purpose of this study is to compare the difference between two different pain control methods in patients who will be having a colorectal surgery

What is the current status of trial NCT03702621?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2018-08-30. Estimated completion is 2020-03-13.

What conditions does trial NCT03702621 study?

This clinical trial studies the following conditions: Colorectal Surgery. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03702621?

The interventions under investigation include: Bupivacaine Hydrochloride (DRUG), liposomal Bupivacaine (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03702621?

This trial is sponsored by Indiana University, which has 1,026 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03702621 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial